On Tuesday, post the market hours, Aurobindo Pharma announced the receipt of the DCGI’s (Drugs Controller General of India) permission to manufacture and distribute its in-licensed generic version of MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback’s Molnupiravir, to be marketed as Molnaflu®.